Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$23.27 -1.5%	$20.41	$15.47 ▼ $36.37	$796.14M	1.26	201,868 shs	441,320 shs
CPRX Catalyst Pharmaceuticals	$23.53 -3.1%	$23.85	$14.75 ▼ $26.58	$2.87B	0.72	1.13 million shs	1.11 million shs
SRRK Scholar Rock	$32.45 -2.6%	$30.90	$6.76 ▼ $46.98	$3.08B	0.28	1.28 million shs	637,122 shs
VKTX Viking Therapeutics	$26.08 -8.7%	$26.46	$18.92 ▼ $81.73	$2.93B	0.65	4.07 million shs	6.08 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-1.52%	-1.06%	+24.11%	+10.81%	+24.71%
CPRX Catalyst Pharmaceuticals	-3.13%	-9.05%	+0.56%	+11.94%	+52.30%
SRRK Scholar Rock	-2.61%	-5.20%	+6.25%	-6.21%	+245.58%
VKTX Viking Therapeutics	-8.75%	-6.29%	-1.84%	-15.57%	-50.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.4411 of 5 stars	3.6	0.0	0.0	2.9	0.8	0.0
CPRX Catalyst Pharmaceuticals	4.7716 of 5 stars	3.6	2.0	3.9	3.2	3.3	2.5
SRRK Scholar Rock	4.386 of 5 stars	3.6	2.0	4.4	2.9	3.3	0.6
VKTX Viking Therapeutics	4.3941 of 5 stars	4.5	1.0	4.7	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	68.83% Upside
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	39.54% Upside
SRRK Scholar Rock	3.14	Buy	$42.67	31.48% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	234.18% Upside

Current Analyst Ratings Breakdown

Latest AVBP, VKTX, SRRK, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/3/2025	SRRK Scholar Rock	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/17/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
CPRX Catalyst Pharmaceuticals	$534.65M	5.37	$2.19 per share	10.72	$3.30 per share	7.13
SRRK Scholar Rock	$33.19M	92.83	N/A	N/A	$3.12 per share	10.40
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
CPRX Catalyst Pharmaceuticals	$71.41M	$1.57	19.94	11.05	3.31	31.01%	40.79%	34.87%	8/6/2025 (Estimated)
SRRK Scholar Rock	-$165.79M	-$2.53	N/A	N/A	N/A	N/A	-145.60%	-91.83%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-11.93%	-11.57%	7/23/2025 (Estimated)

Latest AVBP, VKTX, SRRK, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
CPRX Catalyst Pharmaceuticals	N/A	5.11	4.92
SRRK Scholar Rock	0.63	3.88	3.88
VKTX Viking Therapeutics	N/A	36.47	36.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CPRX Catalyst Pharmaceuticals	79.22%
SRRK Scholar Rock	91.08%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
CPRX Catalyst Pharmaceuticals	10.40%
SRRK Scholar Rock	13.30%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
CPRX Catalyst Pharmaceuticals	80	121.98 million	106.15 million	Optionable
SRRK Scholar Rock	140	94.95 million	75.64 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	106.20 million	Optionable

AVBP, VKTX, SRRK, and CPRX Headlines

Recent News About These Companies

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?

June 13 at 1:55 PM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Lifted by Compagnie Lombard Odier SCmA

June 13 at 5:54 AM | marketbeat.com

Viking Therapeutics (VKTX) Rises on Expected Developments

June 12 at 8:30 PM | insidermonkey.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 12 at 6:46 PM | zacks.com

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

June 12 at 8:46 AM | finance.yahoo.com

Harbor Capital Advisors Inc. Sells 14,094 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 12 at 4:51 AM | marketbeat.com

Viking Therapeutics Target of Unusually High Options Trading (NASDAQ:VKTX)

June 12 at 2:42 AM | americanbankingnews.com

Brokers Issue Forecasts for VKTX FY2026 Earnings

June 12 at 1:45 AM | americanbankingnews.com

Analysts Issue Forecasts for VKTX FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Wesbanco Bank Inc. Purchases 12,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 11 at 4:58 AM | marketbeat.com

Viking Therapeutics Target of Unusually Large Options Trading (NASDAQ:VKTX)

June 10, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 7.1% - Still a Buy?

June 10, 2025 | marketbeat.com

Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?

June 9, 2025 | msn.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives $87.15 Average Price Target from Brokerages

June 9, 2025 | americanbankingnews.com

1 Stock Down 34% This Year to Buy and Hold

June 8, 2025 | fool.com

39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLC

June 6, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Analysts

June 6, 2025 | marketbeat.com

Profit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 2, 2025 | marketbeat.com

Deutsche Bank AG Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 2, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires New Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 31, 2025 | marketbeat.com

PKO Investment Management Joint Stock Co Purchases Shares of 15,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, VKTX, SRRK, and CPRX Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$23.27 -0.36 (-1.52%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$23.26 -0.02 (-0.06%)

As of 06/13/2025 04:02 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Catalyst Pharmaceuticals NASDAQ:CPRX

$23.53 -0.76 (-3.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$23.80 +0.27 (+1.15%)

As of 06/13/2025 07:44 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Scholar Rock NASDAQ:SRRK

$32.45 -0.87 (-2.61%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$32.51 +0.05 (+0.17%)

As of 06/13/2025 05:50 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$26.08 -2.50 (-8.75%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$26.22 +0.14 (+0.54%)

As of 06/13/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time